DMAA

DMAA is a blank-check company, not an operating business. Management states plainly it "has neither engaged in any operations nor generated any operating revenues to date," and won't until it completes an initial business combination. The FY2025 net income of $5.94M is not earnings in any real sense — it is $8,756,656 of interest earned on the trust account, offset by $2,816,013 of G&A (which itself includes a $1,996,000 non-cash share-issuance expense from gifting 200,000 shares to a sponsor investor). Operating income was actually -$2.82M and operating cash flow was -$539K. So every fundamentals-quality lens is inapplicable: there is no revenue, no margin trend, no ROE to speak of. The negative stockholders' equity of -$7.26M is a SPAC accounting artifact (public shares classified as redeemable temporary equity outside permanent equity), not distress — the real asset is the $231,150,000 placed in trust.

The entire investment case reduces to two numbers: the trust value and the price. Following the $200M IPO, the $30M over-allotment and private placement units, $231,150,000 sits in trust against 23,000,000 public units — roughly $10.05 per share, redeemable. That is your floor. At $10.65 the market is paying about a 6% premium to trust for the option on a deal — fitting given the 'Drugs Made In America' pharma-reshoring theme. That premium is speculation, not value; the target, terms and dilution are entirely unknown.